MA51893A - Ligands de gm-csf ou du récepteur gm-csf destinés à être utilisés dans le traitement d'une malignité hématologique chez un patient ayant subi un allo-hct - Google Patents

Ligands de gm-csf ou du récepteur gm-csf destinés à être utilisés dans le traitement d'une malignité hématologique chez un patient ayant subi un allo-hct

Info

Publication number
MA51893A
MA51893A MA051893A MA51893A MA51893A MA 51893 A MA51893 A MA 51893A MA 051893 A MA051893 A MA 051893A MA 51893 A MA51893 A MA 51893A MA 51893 A MA51893 A MA 51893A
Authority
MA
Morocco
Prior art keywords
csf
malignity
allo
hct
hematological
Prior art date
Application number
MA051893A
Other languages
English (en)
French (fr)
Inventor
Burkhard Becher
Sonia Tugues
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18194549.4A external-priority patent/EP3623382A1/en
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of MA51893A publication Critical patent/MA51893A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA051893A 2018-02-22 2019-02-22 Ligands de gm-csf ou du récepteur gm-csf destinés à être utilisés dans le traitement d'une malignité hématologique chez un patient ayant subi un allo-hct MA51893A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18158169 2018-02-22
EP18189562 2018-08-17
EP18194549.4A EP3623382A1 (en) 2018-09-14 2018-09-14 Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US16/269,572 US11655293B2 (en) 2018-02-22 2019-02-07 Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT

Publications (1)

Publication Number Publication Date
MA51893A true MA51893A (fr) 2020-12-30

Family

ID=67616687

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051893A MA51893A (fr) 2018-02-22 2019-02-22 Ligands de gm-csf ou du récepteur gm-csf destinés à être utilisés dans le traitement d'une malignité hématologique chez un patient ayant subi un allo-hct

Country Status (11)

Country Link
US (3) US11655293B2 (enExample)
EP (1) EP3755715A1 (enExample)
JP (1) JP7278296B2 (enExample)
KR (1) KR20200123434A (enExample)
CN (1) CN111886248B (enExample)
AU (1) AU2019224550A1 (enExample)
BR (1) BR112020017253A2 (enExample)
CA (1) CA3091536A1 (enExample)
MA (1) MA51893A (enExample)
MX (2) MX2020008792A (enExample)
WO (1) WO2019162472A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
MX2022011111A (es) * 2020-03-08 2023-03-02 Humanigen Inc Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante.
CA3229748A1 (en) * 2021-08-26 2023-03-02 Akifumi Kato Bispecific antibody that binds to cd116 and cd131

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1367688A (zh) 1999-04-14 2002-09-04 美国政府卫生与公众服务部 用于诱导对移植物的免疫耐受性的、包含免疫毒素和抑制树突细胞成熟的因子的组合物
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
RU2447085C2 (ru) 2005-05-18 2012-04-10 МорфоСис АГ Анти-gm-csf антитела и их применение
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
US7741450B2 (en) * 2006-02-08 2010-06-22 Morphotek Inc. Antibodies to GM-CSF
MX2008012291A (es) 2006-03-27 2009-01-12 Medimmune Ltd Miembro que enlaza al receptor gm-csf.
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CN104072613A (zh) 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
CA2717987C (en) 2008-04-29 2018-11-13 Micromet Ag Inhibitors of gm-csf and il-17 for therapy
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
PL2643349T3 (pl) 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
CN103827143A (zh) * 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
MA37946B1 (fr) 2012-09-20 2018-09-28 Morphosys Ag Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
US9658228B2 (en) * 2013-01-30 2017-05-23 The Board of Trustees of the Leland University Junior University Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in transplantation patients
JP6490419B2 (ja) 2014-12-24 2019-03-27 学校法人関西医科大学 制御性ｔ細胞分化誘導剤
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT

Also Published As

Publication number Publication date
JP7278296B2 (ja) 2023-05-19
BR112020017253A2 (pt) 2020-12-22
MX2020008792A (es) 2020-10-14
RU2020129401A (ru) 2022-03-22
JP2021514368A (ja) 2021-06-10
US20210070851A1 (en) 2021-03-11
US11655293B2 (en) 2023-05-23
RU2020129401A3 (enExample) 2022-03-22
US20190256587A1 (en) 2019-08-22
KR20200123434A (ko) 2020-10-29
CN111886248B (zh) 2025-03-04
EP3755715A1 (en) 2020-12-30
CA3091536A1 (en) 2019-08-29
WO2019162472A1 (en) 2019-08-29
US20230340100A1 (en) 2023-10-26
MX2023001357A (es) 2023-02-27
US12384839B2 (en) 2025-08-12
AU2019224550A1 (en) 2020-09-17
CN111886248A (zh) 2020-11-03

Similar Documents

Publication Publication Date Title
EP3755805A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF NON-AGE-RELATED HEARING DAMAGE IN AN INDIVIDUAL
EP3661493A4 (en) THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA
EP3873335A4 (en) CHARACTERIZATION OF THERAPEUTIC EFFECTIVENESS OF NEUROSTIMULATION
EP3642667C0 (fr) Lentille de contact d'orthokératologie pour le traitement de la myopie
EP3802798A4 (en) CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) FOR TREATMENT OF CANCER
EP3455205A4 (en) PEPTIDOMIMETICS FOR TREATING A NOVOVIRUS INFECTION
EP3641829A4 (en) INTERFERON PRODRUG FOR TREATMENT OF CANCER
MA50155A (fr) Acides aminés à chaîne ramifiée pour le traitement d'une lésion neuronale
EP3814286A4 (en) Continuous flow wastewater treatment system
EP3778592A4 (en) RADIOPHARMIC AGAINST PSMA FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
MA49131A (fr) Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
EP3790867A4 (en) KDM1A INHIBITORS FOR DISEASE TREATMENT
EP3466447A4 (en) TOPICAL PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SHAPES OF SKIN Wounds and MANUFACTURING METHODS THEREFOR
MA51893A (fr) Ligands de gm-csf ou du récepteur gm-csf destinés à être utilisés dans le traitement d'une malignité hématologique chez un patient ayant subi un allo-hct
EP3846821A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF LIVER DISEASES
EP3403675A4 (en) ADENO-ASSOCIATED VIRUSVIRION FOR USE IN THE TREATMENT OF EPILEPSIA
EP3504204A4 (en) INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES
EP3432892A4 (en) USEFUL MANNOSE-DERIVED ANTAGONISTS FROM FIMH FOR THE TREATMENT OF DISEASES
MA50233A (fr) Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité
EP4069700A4 (en) MACROCYCLES FOR USE IN TREATMENT OF DISEASES
MA55490A (fr) Mutéine de lipocaline pour le traitement de l'asthme
MA43861A (fr) Inhibiteurs il-8 destinés à être utilisés dans le traitement d'une neuropathie périphérique induite par une chimiothérapie
EP3398614A4 (en) AGENTS FOR PREVENTION AND / OR TREATMENT OF MORBUS ALZHEIMER
MA55507A (fr) Macitentan destiné à être utilisé dans le traitement de l'hypertension portopulmonaire
MA44660A (fr) (+)-azasetron destiné à être utilisé dans le traitement de troubles de l'oreille